Hyperpolarized 129Xe MRI for imaging NK cell therapy of lung metastasis

超极化 129Xe MRI 用于肺转移的 NK 细胞治疗成像

基本信息

  • 批准号:
    10646013
  • 负责人:
  • 金额:
    $ 18.93万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-05-01 至 2025-04-30
  • 项目状态:
    未结题

项目摘要

Abstract. Emerging cell-based therapies may greatly improve therapeutic success of cancer treatment. NK cell immunotherapy is particularly important in treatment of pediatric cancers, where information on tumor immunogens is lacking. Recently, there has been increased interest in the use of adoptive transfer of ex-vivo expanded NK cells for the treatment of solid tumors due to their innate features, higher safety compared to T cells and lower cost. This emerging therapy is of particular importance in osteosarcoma where 30-35% of patients die of pulmonary metastases due to a treatment-failure rate of 85% in this patient group. However, an important problem with implementation of cell therapies in the clinic is our inability to readily assess the presence and distribution of therapeutic cells after administration. Visualization of immune cell distribution and migration with non-invasive imaging could offer significant new insight into the progression of immunotherapy between infusion and invasive biopsy or resection. Although there are a number of viable approaches for imaging of immunotherapy, all current strategies have limitations and no technology has been proven as a single solution for longitudinal imaging of cellular immunotherapies. Therefore, it is important to continue pushing the limits of available imaging tools in order to find solutions that would address the pressing clinical needs. Hyperpolarized (HP) 129Xe MRI has recently emerged as a promising modality for direct imaging of respiratory function and gas absorption. Spectral separation between HP 129Xe gas in the airspace, tissue/plasma, and red blood cells permits quantification of gas absorption and exchange. Further, a few exploratory studies have demonstrated that chemical exchange saturation transfer (CEST) of HP 129Xe in perfluorocarbon nanodroplets (PFC NDs) can significantly enhance sensitivity to the presence of PFC ND’s due to a strong chemical shift between 129Xe gas in PFC and water. We see these developments as a tremendous opportunity to develop clinically translatable strategy for imaging NK cell therapy in the lungs. Here we propose to develop foundation for HP 129Xe CEST (hyperCEST) MRI of NK cells in vivo. The secondary goal is identification of imaging biomarkers of functional HP 129Xe MRI that may provide additional insight into response to cell immunotherapy. We will rely on our extensive expertise in (i) synthesis and applications of PFC NDs in biomedical imaging including cell labeling, and (ii) quantitative MRI, multinuclear imaging (13C, 19F, 129Xe) and metabolic imaging. Our hypothesis is that labeling of NK cells with PFC NDs optimized for 129Xe hyperCEST MRI will not adversely affect their functionality and will allow non-invasive NK cell monitoring with high sensitivity and specificity in the lungs. At the completion of these studies we will have a combination of optimized and validated probes for NK cell 129Xe hyperCEST MRI with corresponding imaging protocols that will provide foundation for further development of this promising technology towards clinical translation.
抽象的。新兴的基于细胞的疗法可以大大提高癌症治疗的治疗成功率。NK细胞 免疫疗法在儿科癌症治疗中特别重要, 免疫原缺乏。最近,人们对使用离体细胞的过继转移越来越感兴趣。 扩增的NK细胞用于治疗实体瘤,由于其先天特征,与T细胞相比, 电池和更低的成本。这种新兴疗法在骨肉瘤中特别重要,30-35%的患者 在该患者组中,由于85%的治疗失败率而死于肺转移。然而,一个重要的 在临床中实施细胞疗法的问题是我们不能容易地评估细胞的存在, 给药后治疗细胞的分布。免疫细胞分布和迁移的可视化, 非侵入性成像可以提供重要的新见解,以了解免疫治疗的进展, 和侵入性活检或切除。虽然有许多可行的方法来成像, 免疫疗法,所有目前的策略都有局限性,没有技术已被证明是一个单一的解决方案 用于细胞免疫疗法的纵向成像。因此,重要的是要继续推动极限, 我们将利用现有的成像工具,以找到解决紧迫临床需求的解决方案。超极化 (HP)129 ~(129)Tc MRI最近已成为一种很有前途的方法,用于直接成像呼吸功能和气体 吸收空气空间中的HP 129氦气、组织/血浆和红细胞之间的光谱分离允许 气体吸收和交换的量化。此外,一些探索性研究表明, 在全氟化碳纳米液滴(PFC ND)中HP 129的化学交换饱和转移(CEST)可以 由于129 Ω气体之间的强烈化学位移, 在PFC和水中。我们认为这些发展是一个巨大的机会, 在肺部成像NK细胞治疗的策略。在这里,我们建议为HP 129 CEST开发基础 (hyperCEST)体内NK细胞的MRI。第二个目标是识别功能性肿瘤的成像生物标志物。 HP 129 MRI可以提供对细胞免疫治疗反应的额外见解。我们将依靠 广泛的专业知识,(i)PFC ND在生物医学成像(包括细胞标记)中的合成和应用, 和(ii)定量MRI、多核成像(13 C、19 F、129 F)和代谢成像。我们的假设是 使用针对129 kDa hyperCEST MRI优化的PFC ND标记NK细胞不会对其功能产生不利影响 并且将允许在肺中以高灵敏度和特异性进行非侵入性NK细胞监测。完成时 在这些研究中,我们将有一个优化和验证的NK细胞129 kDa hyperCEST MRI探针的组合 与相应的成像协议,将提供基础,为进一步发展这一有前途的 技术向临床转化。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

James A Bankson其他文献

James A Bankson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('James A Bankson', 18)}}的其他基金

HDO Imaging is a Quantitative Marker of Cerebral Glucose Oxidation
HDO 成像是脑葡萄糖氧化的定量标志物
  • 批准号:
    10687186
  • 财政年份:
    2022
  • 资助金额:
    $ 18.93万
  • 项目类别:
Leveraging Hyperpolarized MRI for Precision Oncology Approaches in Head and Neck Cancer
利用超极化 MRI 实现头颈癌的精准肿瘤学方法
  • 批准号:
    10530043
  • 财政年份:
    2022
  • 资助金额:
    $ 18.93万
  • 项目类别:
Multi-Site Development & Evaluation of a Quantitative 3D Hyperpolarized C-13 MRI Clinical Prostate Cancer Exam
多站点开发
  • 批准号:
    10115625
  • 财政年份:
    2017
  • 资助金额:
    $ 18.93万
  • 项目类别:
FAST IMAGING METHODS FOR HYPERPOLARIZED NUCLEI
超极化核的快速成像方法
  • 批准号:
    8363924
  • 财政年份:
    2011
  • 资助金额:
    $ 18.93万
  • 项目类别:
FAST IMAGING METHODS FOR HYPERPOLARIZED NUCLEI
超极化核的快速成像方法
  • 批准号:
    8171675
  • 财政年份:
    2010
  • 资助金额:
    $ 18.93万
  • 项目类别:
Array Detectors for Accelerated Small Animal MRI
用于加速小动物 MRI 的阵列探测器
  • 批准号:
    6830546
  • 财政年份:
    2004
  • 资助金额:
    $ 18.93万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 18.93万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 18.93万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 18.93万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 18.93万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 18.93万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 18.93万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 18.93万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 18.93万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 18.93万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 18.93万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了